ATF936

ATF936 is an orally bioavailable small molecule that acts as a negative allosteric modulator (calcilytic) of the calcium-sensing receptor (CaSR). Developed by Novartis as a synthetic organic compound in the quinazolinone class, it inhibits CaSR activity to promote rapid and transient release of parathyroid hormone (PTH), which stimulates bone formation. Preclinical studies demonstrated that oral administration of ATF936 increases bone mineral density and improves bone microarchitecture in rats. In healthy humans and animal models, it produces sharp but transient increases in endogenous PTH levels similar to those seen with teriparatide injections. The drug was investigated primarily for osteoporosis as an oral alternative to injectable PTH analogs[1][2][3][6].

Other names

SV2NZO0LAUSV-2NZO0LAUSV 2NZO0LAUUNII-SV2NZO0LAUUNII-SV-2NZO0LAUUNII-SV 2NZO0LAU717103-89-4SCHEMBL3178576SCHEMBL-3178576SCHEMBL 3178576BDBM50308090BDBM-50308090BDBM 50308090DB-087825DB087825DB 087825